>>does it have potential?"
I can say yes with absolute certainty. Will it reach its potential within the next 2 to 5 years? Less certain.
>>"this company has overpromised and under deliverd (sic)"
Again, what "promises"? Like any company, the company stated goals and it has met thiose goals every step of the way. Have those goals been on time? No, not all. Have those goals been met on my time line? Certainly not.
If you are going to go back and finally research, look at all the goals and examine which ones have been accomplished. Here are a few accomplishments:
* Goal was to become a fully reporting company and uplist from Pink Sheets to OTC:BB. Both goals were accomplished within 2 years. After 18 months some were claiming the officers had broken a promise because they had not yet completed filing and uplisted.
* Goal was to complete proof of concept and efficacy for both HIV and Influenza antivirals. Those goals were accomplished and confirmed in later studies.
* Goal was to continue raising funds to complete preclinical testing using the least share dilutive means. The company now has approximately 16 months of operations funding which should allow completion of at least one tox package and IND filing in that time period. Shares have been diluted from an initial 100 million shares to 130 million shares since the IPO, all the while developing a focused pipeline of 4 antivirals. Show me any biopharma, much less a pink sheet, that can boast the same accomplishment. In all that time and development dilution the SP is sitting at 4 to 5 times the IPO. Unheard of in any penny land stock.
* Goal was to get others to pay for testing. Continuing that accomplishment. In each and every test, with the exception of the testing done by Dr. Menon the CRO, all testing has been paid for by others with NNVC only paying for the test product.
* Goal was to take an antiviral through the preclinical process. The company is currently completing the preclinical process for 4 antivirals. It was also to get a drug or two into biodefense testing. As of January 2007, that waws accomplished, and as of Seymour's most recent update, the testing is starting up again.
These are all remarkable accomplishments for any biopharma startup. Have they been on my preferred time line? No. Is the company where I had thought it would be 3 years ago? No. Is it ahead of any biopharma startup with similar goals? Yes. Way ahead. Way, way ahead.
Market Data 
Markets 
AI
